Tuttle K R, Kunau R T, Loveridge N, Mundy G R
Department of Medicine, University of Texas Health Science Center, San Antonio.
J Am Soc Nephrol. 1991 Aug;2(2):191-9. doi: 10.1681/ASN.V22191.
It has been controversial whether increased renal tubular calcium reabsorption contributes to hypercalcemia in patients with malignancies. Moreover, whether this abnormality is associated with volume depletion, a parathyroid hormone-like effect, or other mechanisms has not been clarified. Eight consecutive patients with hypercalcemia due to a variety of tumor types were studied in detail. The glomerular filtration rate (iothalamate clearance) was reduced in all patients (0.98 +/- 0.10 (mean +/- SE) mL/s.1.73 m2; P less than 0.001) compared with normal controls (N = 9) (1.93 +/- 0.08 mL/s.1.73 m2), but it was similar to that in controls matched for renal insufficiency (N = 6) (1.15 +/- 0.05 mL/s.1.73 m2). During hypercalcemia produced by calcium infusion, urinary calcium excretion (millimoles of calcium per liter of glomerular filtrate) was increased in controls with renal insufficiency compared to those with normal renal function (P = 0.028). In all patients with hypercalcemia of malignancy, urinary calcium excretion was decreased compared with controls with renal insufficiency, but it was low in only five of eight patients compared with normal controls. Extracellular fluid volume (iothalamate volume of distribution) was not decreased in any patient, and urinary cAMP and/or plasma parathyroid hormone-like bioactivity were increased in six of eight patients. After treatment with an inhibitor of bone resorption, aminopropylidene 1,1 diphosphonate, abnormal renal calcium handling was not detected if the serum calcium normalized. It was concluded that increased renal tubular calcium reabsorption was consistently present in patients with hypercalcemia of malignancy compared with controls matched for renal insufficiency, but the proportion with the abnormality was underestimated if normal controls were used.(ABSTRACT TRUNCATED AT 250 WORDS)
肾小管钙重吸收增加是否会导致恶性肿瘤患者出现高钙血症一直存在争议。此外,这种异常是否与容量减少、甲状旁腺激素样作用或其他机制有关尚不清楚。我们对连续8例因各种肿瘤类型导致高钙血症的患者进行了详细研究。与正常对照组(N = 9)(1.93 +/- 0.08 mL/s·1.73 m2)相比,所有患者的肾小球滤过率(碘他拉酸盐清除率)均降低(0.98 +/- 0.10(均值 +/- 标准误)mL/s·1.73 m2;P < 0.001),但与肾功能不全匹配的对照组(N = 6)(1.15 +/- 0.05 mL/s·1.73 m2)相似。在钙输注引起高钙血症期间,与肾功能正常的对照组相比,肾功能不全的对照组尿钙排泄(每升肾小球滤液中的钙毫摩尔数)增加(P = 0.028)。在所有恶性肿瘤高钙血症患者中,与肾功能不全的对照组相比,尿钙排泄减少,但与正常对照组相比,8例患者中只有5例较低。所有患者的细胞外液容量(碘他拉酸盐分布容积)均未减少,8例患者中有6例尿cAMP和/或血浆甲状旁腺激素样生物活性增加。用骨吸收抑制剂氨丙基二膦酸盐治疗后,如果血清钙恢复正常,则未检测到异常的肾钙处理。得出的结论是,与肾功能不全匹配的对照组相比,恶性肿瘤高钙血症患者肾小管钙重吸收持续增加,但如果使用正常对照组,异常比例会被低估。(摘要截断于250字)